Dr Andrea Barrio speaks to ecancer at SABCS 2018 about the practical approach to the management of the axilla after neoadjuvant chemotherapy
She explains that the prospective trials that have demonstrated that the false negative rate of sentinel lymph node biopsy in clinically node positive patients after neoadjuvant chemotherapy exceeded the 10% considered to be clinically acceptable but that the number of sentinel nodes received can modify the false negative rate.
She explains that in a recently published meta analysis it was seen that the false negative rate was reduced to 4% when 3 or more sentinel nodes were removed.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
